Literature DB >> 20367800

Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS.

P Jerndal1, G Ringström, P Agerforz, M Karpefors, L M Akkermans, A Bayati, M Simrén.   

Abstract

BACKGROUND: Gastrointestinal (GI)-specific anxiety (GSA) has been proposed to influence symptom severity and quality of life (QOL) in patients with irritable bowel syndrome (IBS). The Visceral Sensitivity Index (VSI) is a recently developed, reliable and valid measure of GSA. Our aim was to evaluate the association between GSA, GI symptom severity, and QOL in IBS patients.
METHODS: Sixty healthy subjects and 306 patients fulfilling the Rome II criteria for IBS were studied. Demographic and disease-related factors were assessed. Patients completed VSI and GI Symptom Rating Scale (GSRS) and questionnaires to determine psychological symptom severity (Hospital Anxiety and Depression Scale), QOL (Short form 36), and presence of functional GI disorders (Rome II Modular Questionnaire). KEY
RESULTS: Compared with healthy subjects, patients with IBS had more severe GSA (34.7 +/- 16.9 vs. 2.2 +/- 4.4 [mean +/- standard deviation]; P < 0.0001). In the IBS group, more severe GSA was seen in patients with more severe GI symptoms (P < 0.0001), general anxiety (P < 0.0001) and depression (P < 0.0001), and with lower socioeconomic status (P < 0.05). In a regression analysis, GSA was the strongest predictor for GI symptom severity (GSRS total score), followed by number of Rome II diagnoses, presence of meal-related IBS symptoms, and gender (R(2) = 0.34). Gastrointestinal-specific anxiety was also, together with general anxiety, depression, socioeconomic status, and gender, found to be independently associated with mental QOL (R(2) = 0.62). CONCLUSIONS & INFERENCES: Gastrointestinal-specific anxiety seems to be an important factor for GI symptom severity and QOL in patients with IBS.

Entities:  

Mesh:

Year:  2010        PMID: 20367800     DOI: 10.1111/j.1365-2982.2010.01493.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  46 in total

1.  Evaluation of health related quality of life in irritable bowel syndrome patients.

Authors:  Raika Jamali; Arsia Jamali; Maryam Poorrahnama; Abdollah Omidi; Bardia Jamali; Neda Moslemi; Reza Ansari; Shahab Dolatshahi; Naser Ebrahimi Daryani
Journal:  Health Qual Life Outcomes       Date:  2012-01-29       Impact factor: 3.186

2.  I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Authors:  Vicente Lorenzo-Zúñiga; Elba Llop; Cristina Suárez; Beatriz Alvarez; Luis Abreu; Jordi Espadaler; Jordi Serra
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Psychosocial determinants of irritable bowel syndrome.

Authors:  Teodora Surdea-Blaga; Adriana Băban; Dan L Dumitrascu
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

4.  Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups.

Authors:  Young Ah Goo; Kevin Cain; Monica Jarrett; Lynne Smith; Joachim Voss; Ernie Tolentino; Joyce Tsuji; Yihsuan S Tsai; Alexandre Panchaud; David R Goodlett; Robert J Shulman; Margaret Heitkemper
Journal:  J Proteome Res       Date:  2012-10-26       Impact factor: 4.466

Review 5.  The intestinal cholinergic anti-inflammatory pathway.

Authors:  Gera Goverse; Michelle Stakenborg; Gianluca Matteoli
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

6.  Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

Authors:  M Simrén; O S Palsson; S Heymen; A Bajor; H Törnblom; W E Whitehead
Journal:  Neurogastroenterol Motil       Date:  2016-08-31       Impact factor: 3.598

7.  Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease.

Authors:  T H Taft; J R Triggs; D A Carlson; L Guadagnoli; K N Tomasino; L Keefer; J E Pandolfino
Journal:  Aliment Pharmacol Ther       Date:  2018-03-12       Impact factor: 8.171

8.  Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome.

Authors:  Mats B O Larsson; Kirsten Tillisch; A D Craig; Maria Engström; Jennifer Labus; Bruce Naliboff; Peter Lundberg; Magnus Ström; Emeran A Mayer; Susanna A Walter
Journal:  Gastroenterology       Date:  2011-11-19       Impact factor: 22.682

9.  Age-related symptom and life quality changes in women with irritable bowel syndrome.

Authors:  Yu-Rong Tang; Wei-Wei Yang; Mei-Lan Liang; Xin-Yu Xu; Mei-Feng Wang; Lin Lin
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

10.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.

Authors:  Ling Lan; Yu-Long Chen; Hao Zhang; Bai-Ling Jia; Yan-Jun Chu; Jin Wang; Shi-Xiao Tang; Guo-Dong Xia
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.